AriBio Oral AR1001 meets the primary efficacy endpoint in a prespecified phase 3 monotherapy population in the POLARIS-AD trial.
AriBio Oral AR1001 meets the primary efficacy endpoint in a prespecified phase 3 monotherapy population in the POLARIS-AD trial.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in